title: Managing the risks of ADHD treatments.
abstract: Pharmacotherapy of attention deficit-hyperactivity disorder (ADHD) is a well-established and effective treatment modality. However, ADHD medications are not without side effects. Understanding the prevalence of adverse events and effective management of risks associated with stimulants and other medications used to treat ADHD is central to broad applicability and effective treatment. This review discusses the literature on the prevalence of adverse events and management strategies employed. We searched online MEDLINE/PubMed and Cochrane databases for articles using several keywords relating to adverse events associated with ADHD medication management. We discuss the relevant data on the significance and prevalence of side effects and adverse events, highlight recent updates in the field, and suggest approaches to clinical management.
authors.affiliation: Division of Child & Adolescent Psychiatry, UCLA Semel Institute for Neuroscience & Human Behavior, 760 Westwood Plaza, Suite 68-251A, Los Angeles, CA, 90024, USA, bschneider@mednet.ucla.edu.
authors.forename: Benjamin N
authors.initials: BN
authors.lastname: Schneider
authors.forename: Michael
authors.initials: M
authors.lastname: Enenbach
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D048788:Growth and Development / Q000187:drug effects; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D012306:Risk; D012308:Risk Management; D012640:Seizures / Q000139:chemically induced; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013981:Tic Disorders / Q000139:chemically induced
chemical_list: D000697:Central Nervous System Stimulants